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Abstract
Introduction: Insulin-like growth factor I (IGF-I) regulates articular cartilage homeostasis. During osteoarthritis (OA),
the anabolic responses of chondrocytes to IGF-I are likely to be prevented by the enhanced production of IGF-
binding proteins (IGFBPs), especially IGFBP-3. The aim of this study is to evaluate whether the architectural
transcription factor high mobility group A1 (HMGA1) influences IGFBP-3 overexpression in vitro, in cultured
chondrocytic cell lines, and ex vivo, in human osteoarthritic cartilage compared to healthy human cartilage
controls.
Methods: Quantitative real-time reverse transcription-PCR (qRT-PCR) was performed to assess the relative transcript
levels of HMGA1 and IGFBP-3 in vitro, in the human chondrocytic cell lines T/C-28a4 and C-28/I2. An
electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP) and transient transfection assays
were performed to investigate the HMGA1-IGFBP-3 gene interaction. Samples of articular cartilage were harvested
from osteoarthritic patients and controls and analyzed by qRT-PCR for HMGA1 and IGFBP-3 mRNA levels.
Results: A parallelism between HMGA1 protein levels and IGFBP-3 gene expression has been observed in T/C-28a4
and C-28/I2 cells. The interaction of HMGA1 with the IGFBP-3 gene promoter has been demonstrated by EMSA and
ChIP. In transient transfections, IGFBP-3 promoter activity increased in cells overexpressing HMGA1 and decreased in
cells pretreated with siRNA detected against HMGA1. IGFBP-3 mRNA expression was higher in cartilage from
patients with OA, where the increased expression of IGFBP-3 closely paralleled the increased expression of HMGA1
mRNA.
Conclusions: Our observations indicate that increased HMGA1 expression in human chondrocytes is associated
with increased expression of IGFBP-3. It is tempting to speculate that, through the regulation of IGFBP3 expression,
HMGA1 may act as a pathogenetic factor for OA.
Introduction
The high-mobility group A1 (HMGA1) protein is a small
nuclear binding protein that participates in various funda-
mental cellular processes, including transcriptional regula-
tion, embryogenesis, cell cycle regulation, transformation
and differentiation, senescence, and DNA repair [1].
By interacting with AT-rich DNA binding sequences,
HMGA1 is able to modify the structure of its target site
and induce structural changes in the DNA to facilitate the
progression of a wide range of DNA-dependent activities
[2]. This interaction enables HMGA1 to recruit additional
transcription factors and alter chromatin structure, leading
to the formation of higher-order transcriptional complexes
called enhanceosomes [3-5]. In concert with other factors,
HMGA1 modulates gene expression and determines
whether the associated genes are switched on or off [6].
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Through such a mechanism, the transcription of cyclo-
oxygenase-2, insulin-like growth factor (IGF)-binding pro-
tein-1 (IGFBP-1), and the insulin receptor is regulated by
HMGA1 [4,5,7,8].
IGFBP-3 is a 38- to 43-kDa protein that regulates the
bioavailability of IGF-I [9]. Detection of IGFBP-3 has been
reported in human chondrocytes in articular cartilage
[10,11]. Several cytokines, matrix metalloproteinases, and
growth factors [10,12-15] take part in the regulation of
articular cartilage homeostasis, and in developing articular
cartilage, IGF-I is an inducer of collagen and aggrecan
synthesis, representing an important factor in the mainte-
nance of the chondrocyte phenotype as well as cartilage
integrity and metabolism. During osteoarthritis (OA), nor-
mal or increased amounts of IGF-I are produced, but
osteoarthritic chondrocytes are hyporesponsive to IGF-I;
this property has been attributed to increased IGFBP levels
that may interfere with IGF-I functionality [16-18].
The role of HMGA1 in OA has not been previously
investigated. For the first time, we provide a comprehen-
sive analysis of the molecular mechanisms underlying the
activation of IGFBP-3 gene transcription in human chon-
drocytes. Using chromatin immunoprecipitation (ChIP)
combined with studies of DNA-protein interaction and
transient transfection assays in living cells, we demon-
strate that HMGA1 modulates the transcription of the
IGFBP-3 gene. Taken together, our findings provide a
mechanistic insight into the molecular processes that
influence IGFBP-3 gene expression in OA.
Materials and methods
Cells and protein extracts
HepG2 human hepatoma cells were cultured in RPMI
1640 medium supplemented with 10% fetal bovine
serum. Because they naturally express both IGFBP-3 and
HMGA1 protein species, these cells were used as a posi-
tive control model. T/C-28a4 and C-28/I2 cells (a kind
gift from Mary B. Goldring, The Hospital for Special Sur-
gery, New York, NY, USA, and Elizaveta Kon, Rizzoli
Orthopedic Institute, Bologna, Italy) were cultured in
high-glucose (4.5 g/L) Dulbecco’s modified Eagle’s med-
ium supplemented with 10% fetal calf serum. Hepatoma,
T/C-28a4, and C-28/I2 cell systems were supplemented
with glutamine (2 mM), penicillin (100 IU/mL), and
streptomycin (100 mg/mL) in a humidified atmosphere
containing 5% CO2 at 37°C. Cytoplasmic and nuclear
extracts were prepared as previously described [19], and
the final protein concentration in the extract was deter-
mined according to the Bradford method (Bio-Rad
Laboratories, Inc., Hercules, CA, USA).
Oligonucleotides and electrophoretic mobility shift assay
Human IGFBP-3 gene promoter sequences were ampli-
fied from genomic DNA by polymerase chain reaction
(PCR) by using the following specific primers: h1 for-
ward, 5’-ATACAGTAATACGAAGTCGCC-3’; h1
reverse, 5’-ACCGGCAAGCGAATGCTCCTT-3’; h2 for-
ward, 5’-TGGGGATATAAACAGCCCAGC-3’; and h2
reverse, 5’-ATACAGCGCTCCGCATTCGTG-3’. Frag-
ments were end-labeled with 32P-dATP and used in an
electrophoretic mobility shift assay (EMSA) as pre-
viously described [19].
Chromatin immunoprecipitation
ChIP was performed as previously described [20] by using
HepG2 cells. Formaldehyde-fixed DNA-protein complexes
were immunoprecipitated with anti-HMGA1 antibody
[19]. The following primers were used to amplify the
region between -295 and -571 base pairs in the IGFBP-3
gene promoter: forward, 5’-TGGGGATATAAACAGCC-
CAGC-3’ and reverse, 5’-GGTCACCCCAGTCACTCCT-
3’. The PCR products were electrophoretically resolved on
a 1.5% agarose gel and visualized by ethidium bromide
staining.
Plasmids and transfections
A human IGFBP-3 reporter plasmid (pGL3-IGFBP-3 Luc)
was constructed by cloning the 1,876-base pair sequence
of the human IGFBP-3 promoter (-1804/+72) into the
pGL3 luciferase reporter vector (Promega Corporation,
Madison, WI, USA) by using the Nhe I and Bgl II sites.
The integrity of this construct was determined by DNA
sequencing. pGL3-IGFBP-3 Luc was transiently trans-
fected into cultured cells together with pcDNA3/HA-
HMGA1 (a generous gift from Guidalbeto Manfioletti,
University of Trieste, Trieste, Italy), pEVR2/Sp1 [4], and
pSG5-C/EBPb [4] vectors in the absence or presence of
HMGA1 small interfering RNA (siRNA) (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) by using the
Lipofectamine 2000 transfection reagent protocol (Invitro-
gen Life Technologies Corporation, Carlsbad, CA, USA).
Luc activity was assayed between 48 and 96 hours later as
previously described [21].
Tissue preparation
The study protocol was approved by the local ethics
committee, and the research was carried out in compli-
ance with the Declaration of Helsinki. Informed written
consent was obtained from all individuals. In total, 28
donors recruited at our outpatient clinic between January
2009 and January 2011 were grouped in two clusters.
The first cluster consisted of 21 patients (10 women and
11 men with a mean age of 67.7 ± 7.7 years) who had OA
(11 hip OA and 10 knee OA) and whose diagnosis was
based on established clinical, biochemical, and radiologi-
cal criteria [22,23]; all patients were subjected to total
joint replacement. A radiological classification of each
osteoarthritic joint was carried out according to the
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Kellgren-Lawrence [24] or Ahlbäck [25] scales. X-rays
were independently evaluated by two musculoskeletal
radiologists, who were unaware of the clinical character-
istics of the patients, and the same measurements were
repeated twice on two separate days. Cohen’s kappa coef-
ficients for interobserver and intraobserver reliability of
scoring were 0.80 and 0.84, respectively. A consensus
decision on the scores was reached in a final common
readout, and a severe OA grade was noted in all patients
(that is, five cases of grade III/IV hip OA, six cases of
grade IV/IV hip OA, six cases of grade IV/V knee OA,
and four cases of grade V/V knee OA). Patients with sec-
ondary OA or those who were previously subjected to
intra-articular injections of corticosteroids, hyaluronic
acid, or non-steroidal anti-inflammatory drugs were
excluded from the study. The second cluster consisted of
seven healthy donors (three women and four men with a
mean age of 41.6 ± 10.7 years) with no OA or other dis-
eases that may potentially alter the articular cartilage.
Samples of articular cartilage were obtained as discarded
surgical material in both clusters of patients. Specifically,
cartilage was taken from the femoral head in patients
with hip OA and from both femoral condyles and the
tibial plateau in patients with knee OA. In the control
group, the donor sites were the knee (three), hip (two),
shoulder (one), and the proximal interphalangeal joint of
the foot (one). All patients observed a pain medication-
free interval 30 days prior to surgery. After the cartilage
was removed from the joint, it was extensively washed
with an isotonic saline solution to remove residual blood
or synovial fluid. Specimens were excised from the super-
ficial and deep layers of the articular cartilage by using
disposable scalpel blades, avoiding the calcified layer and
the subchondral bone. Approximately 0.5 cm3 of cartilage
was dissected from the rim of the ulcer present in all spe-
cimens from patients with OA, and an equal amount of
tissue was taken far from the ulcer. This procedure of
pooling together different samples of cartilage from the
same joint overcomes, at least in part, the possible bias
originating from the presence of non-homogenous
osteoarthritic damage throughout the joint or the effect
of a random choice of the tissue to be harvested. Samples
were pooled, immediately immersed in liquid nitrogen,
and stored at -80°C until analysis. Whole cartilage from
healthy donors was similarly preserved.
RNA preparation and qRT-PCR
Total cellular RNA was extracted from T/C-28a4 and C-
28/I2 cultured cells by using the RNAqueous-4PCR Kit
(Ambion, Austin, TX, USA). RNA isolation from carti-
lage samples was performed by using the TRI Reagent
solution protocol (Ambion). The isolated RNA was sub-
jected to DnaseI treatment, and cDNA was synthesized
from 1 μg of total RNA. Both the yield of RNA and the
260/280 absorbance ratio were similar between samples
obtained from osteoarthritic and healthy cartilage (data
not shown). cDNA (10 ng) was used as a template in the
quantitative real-time reverse transcription-PCR (qRT-
PCR) reaction by using SYBR Green dye. Product accu-
mulation was monitored with a Mastercycler ep Realplex
(Eppendorf, Wesseling-Berzdorf, Germany) detection sys-
tem. The mean cycle threshold (Ct) value was calculated
from triplicate samples and used to determine the gene
expression level. The sample ΔCt (SΔCt) value was calcu-
lated as the difference between the ribosomal protein S9
(RPS9) Ct and sample Ct values. The expression levels of
type X collagen (ColX), HMGA1, and IGFBP-3 were
expressed versus the control sample ΔCt (CΔCt) values.
It has been previously described that ColX, the standard
marker for chondrocyte hyperthophy [26], overexpresses
in human osteoarthritic cartilage with respect to healthy
adult articular cartilage [13,27-29]. Fold differences with
respect to the control were determined by using the for-
mula R = 2 - (SΔCt - CΔCt), where R represents a rela-
tive quantification. Target and housekeeping genes were
amplified by using the following primers: COLXA1 for-
ward, 5’-ACAGGAATGCCTGTGTCTGCTTTACT-3’,
COLXA1 reverse, 5’-CATTGGGAAGCTGGAGCCA-
CACCTGGTC-3’, HMGA1 forward, 5’-AGGAGCAGT-
GACCCATGCGT-3’; HMGA1 reverse, 5’-TGATGGT
GGGCCTGGGGAAG-3’; IGFBP-3 forward, 5’-TTGCAC
AAAAGACTGCCAAG-3’; IGFBP-3 reverse, 5’-CAAC
ATGTGGTGAGCATTCC-3’; and RPS9 forward, 5’-
CAGCTTCATCTTGCCCTCAT-3’ and RPS9 reverse, 5’-
CTGCTGACGCTTGATGAGAA-3’.
Statistical analysis
Student t test was used to assess the significance of the
differences between values. The analysis of variance was
used to evaluate the comparisons within the transient
transfection assays. To calculate the power (1-b error
probability; two-tailed) achieved by our statistical tests,
we considered the actual sample size, the size of the
observed effect, and the a value of 0.05. SPSS (version
17.0; SPSS Inc., Chicago, IL, USA) and G*Power (version
3.1; Institut für Experimentelle Psychologie, Heinrich
Heine Universität, Dusseldorf, Germany) software were
used for the database construction and the statistical
analysis. A P value of less than 0.05 was considered
significant.
Results
HMGA1 and IGFBP-3 expression in T/C-28a4 and
C-28/I2 cells
As measured by qRT-PCR, IGFBP-3 and HMGA1
mRNA expression was observed in both T/C-28a4 and
C-28/I2 cultured cell lines (Figure 1a). However, this
expression was higher in C-28/I2 cells, and this may be
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Figure 1 IGFBP-3 and HMGA1 mRNA expression in chondrocytic cell lines. (a) A comparison of IGFBP-3 and HMGA1 mRNA abundance is
shown in T/C-28a4 (black columns) and C-28/I2 (gray columns) cells following qRT-PCR of total RNA from three separate experiments.
*P = 0.0016; **P = 0.0005. (b) IGFBP-3 and HMGA1 mRNA as measured by qRT-PCR from cultured C-28/I2 cells pretreated with small interfering
RNA directed against HMGA1 (gray columns) or untreated (black columns). *P = 0.0046; **P = 0.0004. (c) qRT-PCR of IGFBP-3 and HMGA1 mRNA
in T/C-28a4 cells transfected with a pcDNA3/HA-HMGA1 expression vector (gray columns) or untransfected (black columns). *P = 0.0039;
**P = 0.0031. Each column indicates the mean value; the error bars indicate standard deviation. HMGA1, high-mobility group A1; IGFBP-3, insulin-
like growth factor binding protein 3; qRT-PCR, quantitative real-time reverse transcription-polymerase chain reaction.
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consistent with the fact that these cells resemble pri-
mary chondrocytes more closely than T/C-28a4 cells do
[30]. IGFBP-3 mRNA abundance in both cell lines clo-
sely paralleled HMGA1 mRNA production, suggesting
that HMGA1 may play a role in IGFBP-3 gene activa-
tion. To examine further the role of HMGA1 in this
event, we carried out experiments in C-28/I2 cells trea-
ted with siRNA directed against HMGA1. As shown in
Figure 1b, a contextual significant decrease in both
IGFBP-3 and HMGA1 mRNA levels was observed in
C-28/I2 cells following transfection with HMGA1
siRNA. Conversely, an increase in IGFBP-3 expression
was observed in T/C-28a4 cells following transfection
with a pcDNA3/HA-HMGA1 expression plasmid that
induced HMGA1 overexpression (Figure 1c). Taken
together, these results indicate that a parallelism exists
between IGFBP-3 and HMGA1 mRNA expression in
chondrocytic cell lines.
Physical interaction of HMGA1 with the IGFBP-3 promoter
A schematic representation of the promoter region of the
human IGFBP-3 gene is shown in Figure 2. Consensus
transcription factor-binding sites within this region were
explored by searching the TRANSFAC database by using
MatInspector [31]. Putative binding sites for HMGA1
were identified together with consensus sites for the
CAAT-enhancer binding protein b (C/EBPb) and the
ubiquitously expressed transcription factor Sp1. We
focused on HMGA1 cis-sites surrounding the first 900
base pairs upstream of the transcriptional start site,
which are usually associated with a more intense promo-
ter activity [4]. DNA-HMGA1 protein interaction was
characterized in vitro by EMSA by using the sequence-
specific radiolabeled fragments h1 and h2, which include
HMGA1 cis-sites flanking the Sp1 and C/EBPb DNA
binding motifs. As shown in Figure 2, binding of a pure
recombinant HMGA1 isoform to these probes produced
a protein-DNA complex that was recognized by the anti-
HMGA1-specific antibody and was supershifted to a
slower-migrating form. No DNA-HMGA1 protein inter-
action was observed when a non-AT-rich sequence of
the IGFBP-3 gene promoter was used as a probe. The
interaction of HMGA1 with the IGFBP-3 gene promoter
was further explored in this study by ChIP analysis by
using HepG2 cells, which naturally express HMGA1. As
shown in Figure 3, binding of endogenous HMGA1
occurred at the IGFBP-3 gene locus in intact HepG2
cells. However, when HMGA1 expression was perturbed
in HepG2 cells treated with siRNA directed against
HMGA1, the DNA binding ability of HMGA1 was signif-
icantly reduced. This finding indicates that HMGA1
binds directly to the IGFBP-3 gene promoter and sug-
gests a molecular mechanism for HMGA1-based stimula-
tion of IGFBP-3 gene expression.
HMGA1 is required for full activation of IGFBP-3 gene
transcription
Considering the observation that a physical interaction
occurs between HMGA1 and the human IGFBP-3 pro-
moter, we next investigated the functional significance of
this DNA-protein interaction. To this end, HepG2 cells
were transiently transfected with a human IGFBP-3-Luc
reporter plasmid in the presence or absence of expression
vectors containing HMGA1, Sp1, or C/EBPb. As shown
Figure 2 Physical interaction of HMGA1 with the IGFBP-3 promoter. In the upper panel, a schematic representation of the IGFBP-3 gene is
shown with HMGA1, Sp1, and C/EBPb DNA binding sites. h1 and h2 are IGFBP-3 DNA sequences that were used as probes. In the lower panel,
EMSAs were performed by using the h1 and h2 DNA probes in the absence (-) and presence (+) of pure HMGA1 (5 ng). The non-AT-rich
sequence was used as a negative control probe. C/EBPb, CAAT-enhancer binding protein b; EMSA, electrophoretic mobility shift assay; HMGA1,
high-mobility group A1; IGFBP-3, insulin-like growth factor binding protein 3.
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in Figure 4, IGFBP-3-Luc activity was enhanced in
HepG2 cells overexpressing HMGA1. Induction of
IGFBP-3-Luc activity markedly increased when both Sp1
and C/EBPb were transfected simultaneously, implying
that these nuclear factors function together to induce full
IGFBP-3 gene transcription. Interestingly, the effect of
Sp1 and C/EBPb was blocked by treating cells with
siRNA directed against HMGA1, confirming that
HMGA1 plays a role in this process.
HMGA1 and IGFBP-3 mRNA expression in patients with
osteoarthritis
Increased IGFBP-3 protein expression has been pre-
viously reported in the cartilage of patients with OA
[32,33]. Considering the above findings, which indicate
that a functional relationship between HMGA1 and
IGFBP-3 does indeed exist, we carried out studies in
osteoarthritic human cartilage. As shown in Figure 5,
IGFBP-3 mRNA expression, as measured by qRT-PCR,
was significantly higher in cartilage from patients with
OA compared with cartilage from healthy donors. Inter-
estingly, the increased expression of IGFBP-3 in these
patients closely paralleled the increased levels of HMGA1
mRNA, and this supports the hypothesis that HMGA1
may be responsible for IGFBP-3 overexpression in chon-
drocytes from patients with OA. Power analyses showed
that the statistical tests used to compare ColX, IGFBP-3,
and HMGA1 mRNA expression between cartilage from
patients with OA and healthy donors had 99% power to
detect the observed differences.
Discussion
A key role for IGFBP-3 in modulating IGF-I bioavailabil-
ity in human chondrocytes has been suggested previously
[11,16-18,34]. However, the molecular mechanisms
Figure 3 ChIP of the IGFBP-3 gene promoter. HepG2 cells, either untreated (U) or treated (T) with small interfering RNA directed against
HMGA1, were used for ChIP of the IGFBP-3 gene by using a polyclonal antibody against HMGA1. There were three separate experiments. ChIP,
chromatin immunoprecipitation; HMGA1, high-mobility group A1; IGFBP-3, insulin-like growth factor binding protein 3.
Figure 4 Functional significance of HMGA1 for IGFBP-3 gene
transcription. HepG2 cells were transfected with the pGL3-IGFBP-3
Luc reporter plasmid (1 μg) in the presence of the indicated
effector vectors (0.5 μg each, black columns). Empty column
indicates mock (no DNA). Functional analysis with small interfering
RNA directed against HMGA1 (100 pmol) is shown in the gray
column. Transcriptional activity of the IGFBP-3 promoter is shown as
the ratio of Luc activity to Renilla activity (Luc/Ren). Columns
indicate mean values; error bars denote standard deviation. There
were three separate experiments. *P = 0.03; **P < 0.0001; ***P <
0.0001. C/EBPb, CAAT-enhancer binding protein b; HMGA1, high-
mobility group A1; IGFBP-3, insulin-like growth factor binding
protein 3.
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regulating expression in chondrocytes are still unknown.
The possibility that HMGA1 plays a role in IGFBP-3
gene regulation is supported by the data in our present
study, indicating that transactivation of the IGFBP-3 gene
by the nuclear transcription factors Sp1 and C/EBPb is
dependent on HMGA1.
In our study, the functional link between HMGA1 and
IGFBP-3 was initially evaluated by molecular biological
techniques and gene expression analyses in both T/C-
28a4 and C-28/I2 chondrocytic cultured cells, which are
two in vitro cell models that are commonly used for stu-
dies on articular cartilage pathophysiology [30]. Our
results clearly indicate that HMGA1 positively modu-
lates IGFBP-3 gene expression in both chondrocyte cell
lines. This finding is in apparent contrast to previous
observations indicating that downregulation of the
IGFBP-3 gene by HMGA1 occurs in mouse C2C12 cells
that stably overexpress HMGA1 [35]. An explanation
for this apparent discrepancy could be that the sustained
induced overexpression of HMGA1 in C2C12 cells may
severely preclude IGFBP-3 expression by preventing
myoblast differentiation. This possibility is supported by
the fact that the expression of both myogenin and
MyoD, two key players in muscle cell differentiation
[36,37], is abolished in C2C12 cells constitutively
expressing HMGA1. Furthermore, the cell specificity of
HMGA1 action should be considered. In this respect, a
differential role of HMGA1 as either an activator or an
inhibitor of cellular biological processes has been
documented [1]. The in vitro data in cultured chondro-
cytes were confirmed in articular cartilage samples from
patients with OA. In agreement with previous studies
[32,33], IGFBP-3 levels were increased in the cartilage of
patients with OA, and a parallel increase in HMGA1
expression was detected simultaneously. To the best of
our knowledge, this latter observation has not been
reported before, and the increase in HMGA1 expression
in these patients constitutes a novel finding in this
study. We next observed an overexpression of type X
collagen in osteoarthritic cartilage. However, caution
should be exerted in interpreting this overexpression
because conflicting results have been published for the
expression of this collagen type in OA [26].
Autocrine IGFBP-3 production in intact cartilage has
been reported [32]. Notably, the increase of IGFBP-3
during OA may affect the integrity of articular cartilage,
diminishing the synthesis of matrix collagen and aggre-
can [9,13].
IGF-I functions in the stimulation and maintenance of
the chondrocyte phenotype principally in immature carti-
lage [38]. Therefore, the reduced IGF-I bioavailability in
OA might influence chondroptosis, thus creating cell-
depleted cartilage [39-41]. An increase in IGFBP protein
production has been widely demonstrated in both the
articular cartilage and synovial fluid from patients with
OA [16,34,42,43], and the increased amount of IGFBP-3
has been directly associated with the severity of the dis-
ease [32]. IGFBP-3 overexpression has been reported in
the extracellular cartilage matrix and within both the
cytoplasm and nuclear environment of osteoarthritic
chondrocytes [11]. Cellular segregation of IGFBP-3 might
also deliver IGF-independent signals [34]. Notably, the
nuclear presence of IGFBP-3 in chondrocytes has been
associated with the regulation of cell division and apopto-
sis [11]. However, the possibility that HMGA1 plays a
direct role in chondroptosis cannot be excluded, and this
possibility is consistent with data in the literature, indi-
cating that apoptosis in non-neoplastic cells can be
induced by HMGA1 [44]. Finally, a possible role for
HMGA1 and IGFBP-3 in response to OA-induced
hypoxia can be hypothesized. Indeed, hypoxia is involved
in the pathogenesis of several musculoskeletal diseases
[45,46] and is able to induce IGFBP-3 via HIF-1a in a
wide range of cell cultures [47,48]. It has also been
demonstrated that hypoxia increases the expression of
HMGA proteins [7].
Conclusions
Collectively, our data indicate that IGFBP-3 expression
is increased both in the C-28/I2 chondrocytic cell line
and in the chondrocytes of osteoarthritic patients in
comparison with T/C-28a4 cell line and healthy human
cartilage controls, respectively. Given our observations
Figure 5 ColX, IGFBP-3, and HMGA1 mRNA levels in
osteoarthritis. ColX (left), IGFBP-3 (center), and HMGA1 (right) mRNA
expression in human chondrocytes from healthy donors (black
columns) and from patients with osteoarthritis (gray columns), as
measured by quantitative real-time reverse transcription-polymerase
chain reaction of total RNA. Columns indicate mean values; error bars
denote standard deviation. *P < 0.0001; **P = 0.0045; ***P = 0.0022.
ColX, type X collagen; HMGA1, high-mobility group A1; IGFBP-3,
insulin-like growth factor binding protein 3.
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that HMGA1 is implicated in the upregulation of
IGFBP-3 protein expression, it is tempting to hypothe-
size that HMGA1 acts as a regulator of articular carti-
lage homeostasis. Future studies will further clarify the
role of HMGA1 in the pathomechanisms of OA.
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